Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE011 (ITA) (Dr. Jansen)
· consented 2023-03-13
Adverse events
5
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
severe
serious
assessed
2026-08-18
Grade 4 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-04-07 (study day 15); relationship: not assessed; serious criteria: life-threatening
moderate
assessed
2026-08-18
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-05-06 (study day 44); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-06-09 (study day 78); relationship: not assessed
severe
assessed
2026-08-18
Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-06-18 (study day 87); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-06-28 (study day 97); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.